Cardiovascular Pharmaceuticals Market - India
June 2014
2CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
Drivers:
Increasing patient base
Patent expiry of blockbuster dr...
3
•Macro-Economic Indicators
•Introduction
•Market Overview
•Market Value Chain
•Drivers & Challenges
•Government Initiati...
4
Indian cardiovascular pharma market is expected to witness
huge growth in the coming years
Indian Market – Overview Mark...
5
Drivers & Challenges - Summary
Drivers
Increasing patient base
Patent expiry of blockbuster drugs
Increasing disposable ...
6
Government Initiatives – Summary
Government
Initiatives
Reduction in drug prices
Control programs Changes in tax structu...
7
Porter’s Five Forces Analysis
Competitive Rivalry
• Texttext texttext texttext texttext
texttext texttext
• Texttext tex...
8
Competitive Benchmarking (1/5)
Public Trading Comparables (FY 20--) – Top 4 Companies
Company 1 Company 2 Company 3 Comp...
9
Public: Domestic Company – A Company (1/4)
Key People
Products and Services
Company Information Offices and Centres – In...
10
Source:
Key Ratios
Financial Summary
Public: Domestic Company – A Company (2/4)
• The company incurred a net loss of IN...
11
Public: Domestic Company – A Company (3/4)
y
x
20--
z y
x
20--
z y
x
20--
z
y
x
20--
z
onm
Key Business Segments
20--
z...
12
Public: Foreign Company – XX (4/4)
•Texttext texttext texttext texttext
texttext texttext
•Texttext texttext texttext t...
13CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
Private: Domestic Company – XXXXX XXXXX Ltd. (1/5)
Key People
Pro...
14
Private: Domestic Company – XXXXX XXXXX Ltd. (2/5)
Shareholders of the Company Ownership Structure
Name No. of Shares h...
15CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
Financial Snapshot Key Ratios
Financial Summary
• The company inc...
16CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
Business Highlights
Description News
Overview
• Is a vertically i...
17CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
Private: Domestic Company – XXXXX XXXXX Ltd. – SWOT
Analysis (5/5...
18CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
Thank you for the attention
About Netscribes, Inc.
Netscribes, In...
Upcoming SlideShare
Loading in …5
×

Market Research Report : Cardiovascular Pharmaceuticals Market in India 2014 - Sample

1,122 views

Published on

For the complete report, get in touch with us at : info@netscribes.com
Abstract:
Netscribes latest market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide
Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well
Coverage
Overview of the Cardiovascular Pharmaceutical market in India and historical and forecasted market size data over 2013 to 2018e
Segmentation of the Cardiovascular Pharmaceutical market and value chain analysis
Qualitative analysis of market drivers, challenges, trends and regulatory measures taken by the government
Overview of the various industry bodies and their responsibilities
Analysis of the competitive landscape and detailed profiles of major players

Published in: Business, Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,122
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
39
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Market Research Report : Cardiovascular Pharmaceuticals Market in India 2014 - Sample

  1. 1. Cardiovascular Pharmaceuticals Market - India June 2014
  2. 2. 2CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT Drivers: Increasing patient base Patent expiry of blockbuster drugs Increasing disposable income Introduction of new drugs Drug regulation and patents  Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20--  The market is expected to grow at a CAGR of y% from 20-----  CVD segment is the second largest contributor to domestic sales, contributing around x % Challenges:  Strong competition  Competition from complementary and alternative medicines  Drug value chain  Phases of clinical trial  Approval and licensing of drugs  Patent approvals Competition  Highly fragmented market with large number of players Drivers and Challenges Market Executive Summary Government initiatives  Reduction in drug prices  Changes in tax structure  Control Programmes Major Public Companies Major Private Companies Company 1 Company 4 Company 7 Company 10 Company 2 Company 5 Company 8 Company 11 Company 3 Company 6 Company 9 Company 12 Company 1 Company 4 Company 2 Company 3  Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20--  The market is expected to grow at a CAGR of y% from 20-----  CVD segment is the second largest contributor to domestic sales, contributing around x % Market
  3. 3. 3 •Macro-Economic Indicators •Introduction •Market Overview •Market Value Chain •Drivers & Challenges •Government Initiatives •Regulation and Patents •Competitive Landscape •Recent Developments •Strategic Recommendations •Appendix CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  4. 4. 4 Indian cardiovascular pharma market is expected to witness huge growth in the coming years Indian Market – Overview Market Size and Growth Source: 0 50 100 150 INR bn y% 2015e x6 2014e x5 2013e x4 2012e x3 2011e x2 2010 x 1 Top Pharmaceutical Segments – 20-- 0 2 4 6 8 10 12 14 16 18 % oncology Y 10 urology y 9 gynaecology Y 8 pain y 7 diabetes Y 6 respiratory Y 5 CNS Y 4 gastro Y 3 CVD Y 2 anti-infectives Y 1 • Cardiovascular therapeutic segment belongs to the chronic segment (comprising of cardiovascular, anti diabetics and neuro pshychiatry), which together account for around A% of the total pharma market • Cardiovascular segment is the second largest contributor to domestic pharmaceuticals market sales, with a share of x%  Within the cardiovascular segment, antihypertensive drugs account for almost m% of revenue  Cholesterol lowering drugs account for one third of sales • Presently the market has a size of INR X bn and is expected to grow at a CAGR of y% from 20-- to 20-- to reach INR Y bn • Annually, B million Indians die of cardiovascular diseases • According to WHO estimates, by 2020, almost a% of cardiac patients worldwide will be Indian CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  5. 5. 5 Drivers & Challenges - Summary Drivers Increasing patient base Patent expiry of blockbuster drugs Increasing disposable income Introduction of new drugs Challenges Strong competition Competition from complementary and alternative medicines CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  6. 6. 6 Government Initiatives – Summary Government Initiatives Reduction in drug prices Control programs Changes in tax structure CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  7. 7. 7 Porter’s Five Forces Analysis Competitive Rivalry • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext Bargaining Power of Buyers • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext Threat of New Entrants • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext Impact Low to Medium Impact Medium to High Impact High Bargaining Power of Suppliers • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext Impact Low to Medium Threat of Substitutes • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext • Texttext texttext texttext texttext texttext texttext Impact Low SAMPLE CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  8. 8. 8 Competitive Benchmarking (1/5) Public Trading Comparables (FY 20--) – Top 4 Companies Company 1 Company 2 Company 3 Company 4 Market Capitalization (xx) Share Price (xx) EV/EBITDA (xx) EV/Revenue (xx) PE Ratio Note: Top 3 Public companies based on the Market Capitalization, Share Price and PE ratio is as of 24/03/2014 CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  9. 9. 9 Public: Domestic Company – A Company (1/4) Key People Products and Services Company Information Offices and Centres – India Corporate Address X Road Bangalore Tel No. +91 xx xxxxx xxxxx Fax No. +91 xx xxxxx xxxxx Website www.ppp.com Year of Incorporation 19-- Ticker Symbol xxxxxx Stock Exchange NNN Name Designation Person M Founder Person N CFO Person O Head Person Q President City AProducts and Services Head Office Source: Category Products/Services Pharmaceutical CVD, CNS, respiratory, dermatology, orthopedics, nutritional, urology, anti- infectives Molecule Development Infectious diseases, metabolic diseases, inflammatory/respiratory diseases, and oncology CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  10. 10. 10 Source: Key Ratios Financial Summary Public: Domestic Company – A Company (2/4) • The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20-- • The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20-- • The company earned an operating margin of x per cent in FY 20-- a decrease of y percentage points over FY 20-- • The company reported debt to equity ratio of x in FY 20--, an increase of y per cent over FY 20-- Financial Summary Profit / Loss Revenue Profit INR mn p n 0 -m Revenue INR mn 0 20-- t p 20-- s o 20-- r n 20-- q m 10,000 5,000 Indicators Present Value Market Capitalization (INR) X units Total Enterprise Value (INR) Y units EPS (INR) Z units PE Ratio (Absolute) A Particulars y-o-y change 20-- 20-- 20-- 20-- Profitability Ratios Operating Margin Net Margin Profit Before Tax Margin Return on Equity Return on Capital Employed Return on Working Capital Return on Assets Return on Fixed Assets Cost Ratios Operating costs (% of Sales) Administration costs (% of Sales) Interest costs (% of Sales) Liquidity Ratios Current Ratio Cash Ratio Leverage Ratios Debt to Equity Ratio Debt to Capital Ratio Interest Coverage Ratio Efficiency Ratios Fixed Asset Turnover Asset Turnover Current Asset Turnover Working Capital Turnover Capital Employed Turnover Improved Decline Financial Snapshot CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  11. 11. 11 Public: Domestic Company – A Company (3/4) y x 20-- z y x 20-- z y x 20-- z y x 20-- z onm Key Business Segments 20-- z y x 20-- z y x 20-- z y x 20-- z y x x y z Key Geographic Segments Source: Key Recent Developments Description News Overview • Company A is an integrated research based company that produces a wide range of generic medicines • Serves customers in over 100 countries with manufacturing facilities in several countries Cardiovascular Pharmaceuticals • Products include include Product 1 and Product 2 Key Initiatives • Is making consistent effort for continual improvement in rural areas with respect to accessibility of medicines CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  12. 12. 12 Public: Foreign Company – XX (4/4) •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •. •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext TO WS CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  13. 13. 13CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT Private: Domestic Company – XXXXX XXXXX Ltd. (1/5) Key People Products and Services Company Information Offices and Centres – India Corporate Address Xxxxx xxxxxx xxxxx xxxxxx Road xxxxxxxxx 3-------- Gujarat Tel No. +91 xx xxxx xxxx Fax No. +91 xx xxxx xxxx Website www.hhh.com Year of Incorporation 19-- Category Products/Services Pharmaceutical Products Therapeutic areas like neurology, psychiatry, cardiology, pain management, gastroenterology etc. Biotechnology Chronic diseases like oncology and nephrology by subsidiary Intas Biopharmaceuticals Ltd. Name Designation Person 1 Founder and Chairman Person 2 MD Person 3 CFO Head Office City A
  14. 14. 14 Private: Domestic Company – XXXXX XXXXX Ltd. (2/5) Shareholders of the Company Ownership Structure Name No. of Shares held Shareholder 1 47,---,---,--- Shareholder 2 11,---,--- Shareholder 3 6,---,--- Shareholder 4 6,---,--- Shareholder 5 6,---,--- Shareholder 6 6,---,--- Shareholder 7 6,---,--- Shareholder 8 21,---,--- Total 114,---,--- Note: Shareholding pattern as on AGM dated 31st Mar 2013 16.2% 46.4% 37.5% Xxxxxx xxxxxxx xxxxx Xxxxxx xxxxxx Xxxxxxxx xxxxxx CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT
  15. 15. 15CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT Financial Snapshot Key Ratios Financial Summary • The company incurred a net loss of INR xx mn in FY 20--, as compared to net profit of INR yy mn in FY 20-- • The company reported total income of INR xx bn in FY 20--, registering an increase of yy per cent over FY 20-- • The company earned an operating margin of x per cent in FY 20-- a decrease of y percentage points over FY 20-- • The company reported debt to equity ratio of x in FY 20--, an increase of y per cent over FY 20-- Particulars y-o-y change (2013-12) 2013 2012 2011 2010 Profitability Ratios Operating Margin Net Margin Profit Before Tax Margin Return on Equity Return on Capital Employed Return on Working Capital Return on Assets Return on Fixed Assets Cost Ratios Operating costs (% of Sales) Administration costs (% of Sales) Interest costs (% of Sales) Liquidity Ratios Current Ratio Cash Ratio Leverage Ratios Debt to Equity Ratio Debt to Capital Ratio Interest Coverage Ratio Efficiency Ratios Fixed Asset Turnover Asset Turnover Current Asset Turnover Working Capital Turnover Capital Employed Turnover Improved Decline Private: Domestic Company – XXXXX XXXXX Ltd. (3/5) Profit / Loss Revenue Profit INR mn p n 0 -m Revenue INR mn 0 20-- t p 20-- s o 20-- r n 20-- q m 10,000 5,000
  16. 16. 16CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT Business Highlights Description News Overview • Is a vertically integrated global pharmaceutical formulation development company involved in manufacturing and marketing • Operates 4 subsidiaries operating in different business segments • Has presence in over xx countries with successful contract manufacturing and contract marketing tie-ups across the world predominantly in xx, yy and zz Cardiovascular Pharmaceutical • Has T products in its xx product segment under M10, N, O and P brand names • Has xx products in its RR product segment under brand names like A, B, C, D, E, F, G, Q, R, S, T, U, V, W, X, Y, and Z Key initiatives • XXX received an outstanding review for itself for developmental works like The Y Project scholarships for students and V Journals Private: Domestic Company – XXXXX XXXXX Ltd. (4/5)
  17. 17. 17CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT Private: Domestic Company – XXXXX XXXXX Ltd. – SWOT Analysis (5/5) •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext •Texttext texttext texttext texttext texttext texttext TO WS
  18. 18. 18CARDIOVASCULAR PHARMACEUTICAL MARKET IN INDIA 2014.PPT Thank you for the attention About Netscribes, Inc. Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives. Cardiovascular Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Series. For any queries or customized research requirements, contact us at: Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction. Phone: +91 22 4098 7600 E-Mail: info@netscribes.com

×